Dear Members,
Your Director's hereby present the Eighteenth Board's Report of Aster DM Quality Care
Limited (the 'Company' or 'Aster') together with the Audited Financial Statements
(Consolidated and Standalone) and the Auditors' Report on the business and operations of
your Company for the financial year ended 31 March 2026.
1. RESULTS OF OPERATION AND STATE OF AFFAIRS
Financial Results
(INR in crores except per share data)
|
Standalone |
|
Consolidated |
Particulars |
FY 2026 |
FY 2025 |
FY 2026 |
FY 2025 |
Revenue from operations |
2,615.70 |
2,320.48 |
4,643.22 |
4,138.46 |
| Other income |
155.03 |
5,738.67 |
125.60 |
148.23 |
Total income |
2,770.73 |
8,059.15 |
4,768.82 |
4,286.69 |
| Total expenses |
2,306.61 |
2,094.05 |
4,129.42 |
3,746.58 |
| Profit before exceptional items and tax |
464.12 |
5,965.10 |
639.40 |
540.11 |
| Exceptional items |
(89.92) |
323.15 |
(32.71) |
(50.14) |
| Profit before tax |
374.20 |
6,288.25 |
606.69 |
489.97 |
| Share of net profit/ (loss) of equity accounted investees |
- |
- |
(37.00) |
(18.91) |
| Profit before tax |
374.20 |
6,288.25 |
569.69 |
471.06 |
| Less: Tax expenses |
106.38 |
79.28 |
142.59 |
134.37 |
| Profit for the year from continuing operations |
- |
- |
427.10 |
336.69 |
| Profit for the year from discontinued operations |
- |
- |
- |
5,071.20 |
| Profit for the year |
267.82 |
6,208.97 |
427.10 |
5,407.89 |
| Other comprehensive income/(loss), net of taxes |
(0.16) |
(1.03) |
0.36 |
(2.11) |
| Total comprehensive income for the year |
267.66 |
6,207.94 |
427.46 |
5,405.78 |
| Profit attributable to Owners of the company |
267.82 |
6,207.94 |
388.14 |
5,377.83 |
| Non-controlling interest |
- |
- |
38.96 |
30.06 |
Total |
267.82 |
6,207.94 |
427.10 |
5,407.89 |
| Total comprehensive income attributable to Owners of the company |
267.66 |
6,207.94 |
388.52 |
5,375.79 |
| Non-controlling interest |
- |
- |
38.94 |
29.99 |
Total |
267.66 |
6,207.94 |
427.46 |
5,405.78 |
| Earnings per share |
|
|
|
|
Continuing operations (J) |
|
|
|
|
| Basic |
- |
- |
7.53 |
6.16 |
| Diluted |
- |
- |
7.52 |
6.15 |
Discontinuing operations (J) |
|
|
|
|
| Basic |
- |
- |
- |
101.82 |
| Diluted |
- |
- |
- |
101.70 |
Continuing & Discontinued operations (J) |
|
|
|
|
| Basic |
5.20 |
124.67 |
7.53 |
107.98 |
| Diluted |
5.19 |
124.52 |
7.52 |
107.85 |
Financial position
|
Standalone |
|
Consolidated |
|
Particulars |
|
|
|
|
|
FY 2026 |
FY 2025 |
FY 2026 |
FY 2025 |
| Cash and cash equivalents |
119.44 |
119.84 |
228.07 |
164.59 |
| Trade receivables |
178.94 |
138.13 |
307.23 |
257.81 |
| Other current assets |
1,212.25 |
1,353.65 |
1,412.49 |
1,479.07 |
Total current assets |
1,510.63 |
1,611.62 |
1,947.79 |
1,901.47 |
| Property, plant and equipment (including capital work in progress) |
1,211.47 |
1,076.61 |
3,031.33 |
2,663.28 |
| Goodwill |
- |
- |
264.12 |
264.12 |
|
|
(INR in crores except per share data) |
|
Standalone |
|
Consolidated |
Particulars |
|
|
|
|
|
FY 2026 |
FY 2025 |
FY 2026 |
FY 2025 |
| Other intangible assets (including Intangible asset under development) |
2.08 |
1.25 |
26.27 |
30.32 |
| Other non-current assets |
3,615.86 |
2,275.28 |
2,842.45 |
1,747.19 |
Total non-current assets |
4,829.41 |
3,353.14 |
6,164.17 |
4,704.91 |
Total Assets |
6,340.04 |
4,964.76 |
8,111.96 |
6,606.38 |
| Non-current liabilities |
1,342.61 |
1,204.39 |
2,299.10 |
2,075.72 |
| Current liabilities |
631.21 |
420.88 |
979.16 |
879.21 |
Total current and non-current liabilities |
1,973.82 |
1,625.27 |
3,278.26 |
2,954.93 |
| Equity share capital |
518.13 |
499.52 |
518.13 |
499.52 |
| Other equity |
3,848.09 |
2,839.97 |
4,057.73 |
2,928.55 |
| Non-controlling interest |
- |
- |
257.84 |
223.38 |
Total equity |
4,366.22 |
3,339.49 |
4,833.70 |
3,651.45 |
Total equity and liabilities |
6,340.04 |
4,964.76 |
8,111.96 |
6,606.38 |
Note: The above figures are extracted from the audited standalone and
consolidated financial statements of the Company prepared in accordance with the Indian
Accounting Standards ("Ind AS").
The profitability for FY 2025-26 reflects the Company's continuing healthcare
operations. The previous financial year included exceptional and one-time items relating
to sale of GCC business. Details of exceptional items are provided in Note 43 to the
consolidated financial statements.
2. COMPANY'S PERFORMANCE
During the financial year under review, the Company reported revenue from operations of
INR 2,615.70 crores on a standalone basis, as compared to INR 2,320.48 crores in the
previous financial year.
During the financial year under review, the Company reported revenue from operations of
INR 4,643.22 crores on a consolidated basis, as compared to INR 4138.46 crores in the
previous financial year. Out of the total consolidated revenue from operations for the
financial year 2025-26, the Hospitals and Clinics segment accounted for INR 4,506.39
crores, the Labs segment accounted for INR 153.50 crores, the Wholesale Pharmacy segment
accounted for INR 108.32 crores, and other segment(s) accounted for INR 14.79 crores.
The detailed operational performance of the Company and its various business segments
is comprehensively discussed in the Management Discussion and Analysis Report, which forms
an integral part of this Annual Report.
3. DIVIDEND
During FY 2025-26, the Board declared an interim dividend of INR 3/- per equity share
of face value INR 10/- each. The Board has not recommended any final dividend for FY
2025-26. The total dividend outflow during the year amounted to INR 155.43 crore.
|
FY 2026 |
|
FY 2025 |
|
|
Rate of Dividend per |
|
Rate of Dividend per |
|
Particulars |
Dividend payout* |
Dividend payout* |
|
equity share (Face value of J 10/- each) |
( J crore) |
equity share (Face value of J 10/- each) |
(J crore) |
| Special Dividend |
- |
- |
118 |
5,894.25 |
| Interim Dividend |
3 |
155.43 |
4 |
199.80 |
| Final Dividend |
- |
- |
1 |
51.81 |
*The dividend payout provided is the gross amount before deduction of tax at source by
the Company.
The Dividend Distribution Policy, in terms of Regulation 43A of the Securities and
Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations,
2015 ("Listing Regulations") is available on the Company's website on
https://www.asterqualitycare.com/ investors/corporate-governance/policies
4. UNCLAIMED DIVIDEND ON SHARES
As at March 31, 2026, unclaimed dividend amounting to INR 42,98,144.12/- which
has not been claimed by shareholders of the Company and is lying in the respective Unpaid
Dividend Accounts of the Company.
Your Company has disclosed the statement containing the names and last known addresses
of those shareholders whose dividend is unpaid on the Company's website at https://www.asterqualitycare.com/investors
Membersarerequestedtoclaimdividend(s)whichhaveremained unclaimed, by sending a request to
the Company at e-mail: cs@asterqualitycare.com or to the Company's Registrar to an Issue
and Share Transfer Agent (RTA) at e-mail coimbatore@ in.mpms.mufg.com or to their postal
address MUFG Intime India Private Limited, Surya 35, Mayflower Avenue, Behind Senthil
Nagar, Sowripalayam Road, Coimbatore - 641028.
5. TRANSFER TO RESERVES
There were no appropriations to/from the general reserves of the Company during the
year under review.
6. MERGER UPDATE
During the year under review, a significant milestone was achieved with the successful
completion of the Scheme of Amalgamation under Sections 230 to 232 of the Companies Act,
2013 (the "Scheme") amongst Quality Care India Limited ("QCIL"), Aster
DM Healthcare Limited ("the Company"), and their respective shareholders and
creditors.
Pursuant to the orders of the Hon'ble National Company Law Tribunal ("NCLT"),
Hyderabad Bench, the shareholders and creditors of both companies approved the Scheme at
their respective meetings held on 10 March 2026. Subsequently, the NCLT sanctioned the
Scheme vide its order dated 19 June 2026. The Scheme became effective on 1 July 2026,
marking the culmination of a transformative transaction that brought together two leading
healthcare providers to create one of India's largest integrated healthcare platforms.
Consequent to the Scheme and pursuant to the Certificate of Incorporation issued by the
Ministry of Corporate Affairs ("MCA") on 3 July 2026, the name of the Company
was changed from Aster DM Healthcare Limited to Aster DM Quality Care Limited,
reflecting the combined identity of the merged entity. In accordance with the share
exchange ratio prescribed under the Scheme, the Company allotted 35,35,51,410 equity
shares of INR 10 each on 13 July 2026 to the eligible shareholders of QCIL as on the
Record Date, being 9 July 2026. Further, in accordance with the provisions of the Scheme,
the net proceeds arising from the sale of fractional entitlements, resulting from the
allotment of equity shares pursuant to the merger, shall be distributed to the eligible
shareholders of QCIL in due course.
7. SHARE CAPITAL
During the year under review, there was no change in authorised share capital of
the Company. However, pursuant to implementation of Scheme effective from 1 July 2026, the
Authorised Share Capital of the Company is INR 1,051,70,00,000/- (Indian Rupees One
Thousand and Fifty One Crores and Seventy Lakhs only) divided into 98,20,00,000 (ninety
eight crores and twenty lakhs) equity shares of the face value of INR 10/- (Indian Rupees
Ten only) each, 35,00,000 (thirty five lakh) Preference Shares of INR 10/- (Indian Rupees
Ten Only) each and 1,52,00,000 (one crore and fifty two lakhs) Series A compulsorily
convertible preference shares of the face value of INR 10/- (Indian Rupees Ten only) each
and 5,10,00,000 (five crores ten lakhs) RAR compulsorily convertible preference shares of
the face value of INR 10/- (Indian Rupees Ten only) each.
The paid-up share capital of the Company as on 31 March, 2026, stands at INR 518.12
crores consisting of 51,81,21,029 equity shares of face value of INR 10/- each. During the
year under review, the paid-up equity share capital of your Company increased from INR
499,51,30,600 to INR 5,18,12,10,290 consequent to the allotment of 1,86,07,969 equity
shares of face value of INR 10/- on preferential basis for consideration other than cash
to BCP Asia II Topco IV Pte. Ltd. ("BCP"), and Centella Mauritius Holdings
Limited ("TPG") (collectively referred to as the "Allottees"),
pursuant to special resolution passed by the members of the Company through postal ballot
on December 29, 2024, and pursuant to the Share Acquisition Agreement dated November 29,
2024 ("SAA"). The said consideration was discharged by the way of acquisition of
1,90,46,028 equity shares of QCIL ("Purchase Shares") from the allottees at a
price of INR 445.87/- per equity share which were subsequently cancelled upon
effectiveness of the Scheme. The Company received trading approval for the above-mentioned
shares of the Company from the NSE and the BSE on May 29, 2025. Except as above, there has
been no change in paid-up share capital of the Company during the year under review.
8. DEPOSITS
During the year under review, your Company has not accepted any deposits within the
meaning of Sections 73 and 74 of the Act read together with the Companies (Acceptance of
Deposits) Rules, 2014.
9. PARTICULARS OF LOANS, GUARANTEE AND INVESTMENTS
Details of loans, guarantees and investments covered under Section 186 of the Act form
part of the Notes to the financial statements provided in this Integrated Annual Report.
10. SUBSIDIARIES / JOINT VENTURES AND ASSOCIATES
During the year under review, the Company and its subsidiaries continued to be engaged
in the business of establishing and operating hospitals, clinics and pharmacies in India.
At the beginning of the year, the Company had 20 subsidiaries, including step-down
subsidiaries, and 4 associates. As at March 31, 2026, the Company had 22 subsidiaries and
4 associates, with no significant change in the nature of their business activities.
During the year, Aster DM Super-Specialty Hospital (Sarjapur) Private Limited and Aster DM
Super Specialty Hospital Private Limited (formerly known as Aster DM Super Specialty
Hospital (Yeswanthpur) Private Limited were incorporated as wholly-owned subsidiaries of
the Company.
Pursuant to provisions of Section 129(3) of the Act, a statement containing salient
features of the financial statements of the subsidiaries and associates in Form AOC-1
is annexed as Annexure 1 to this report.
Further, pursuant to the provisions of Section 136 of the Act, the financial statements
of the Company, consolidated financial statements along with relevant documents and
separate audited financial statements in respect of subsidiaries, are available on the
Company's website at https://www.asterqualitycare.com/ investors/financial-information
11. PARTICULARS OF CONTRACTS OR ARRANGEMENTS MADE WITH RELATED PARTIES
During the year under review, all contracts, arrangements and transactions entered into
by the Company with related parties were in the ordinary course of business and on an
arm's length basis. The Company did not enter into any transaction, contract or
arrangement with related parties that could be considered material in accordance with the
Company's policy on dealing with related party transactions. Accordingly, the disclosure
of related party transactions in AOC-2 is not applicable to the Company for the year under
review. Detailed disclosure on related party transactions as per IND AS- 24 have been
provided under Note No. 36 of Standalone Financial Statements.
12. BOARD OF DIRECTORS AND KEY MANAGERIAL PERSONNEL ('KMP')
As at 31 March 2026, the Board consisted of Ten Directors and maintained an optimum mix
of Executive and Non-Executive Directors, including Three Women Directors. Eight Directors
were Non-Executive, of whom Five were Independent Directors. The Board's composition
reflects the Company's commitment to high standards of corporate governance and diversity,
providing an appropriate balance of skills, experience, independence and perspectives
necessary for effective oversight and long-term value creation.
The Company has received declarations from Independent Directors, confirming that they
meet the criteria of independence prescribed under the Act and the Listing Regulations and
that they have complied with the Code for Independent Directors prescribed under Schedule
IV to the Act, and are not disqualified from continuing as Independent Directors. In the
opinion of the Board, all the Independent Directors possess the requisite integrity,
expertise, and experience, and fulfil the conditions specified under the Act and the
Listing Regulations. During the year under review, the Independent Directors of your
Company had no pecuniary relationship or transactions with your Company, other than
sitting fee, commission and reimbursement of expenses, if any.
In terms of Section 150 of the Act read with Rule 6 of the Companies (Appointment and
Qualification of Directors) Rules, 2014, Independent Directors of the Company have
confirmed that they are registered with the databank maintained by the Indian Institute of
Corporate Affairs ("IICA").
In accordance with the provisions of Section 152(6) of the Act, read with the Companies
(Appointment and Qualifications of Directors) Rules, 2014 and the Articles of Association
of the Company, Mr. T J Wilson (DIN: 02135108) is liable to retire by rotation at the
forthcoming AGM of the Company scheduled to be held on September 28, 2026 and being
eligible has offered himself for re-appointment. A resolution seeking Members' approval
for his re-appointment along with other required details forms part of the Notice of the
AGM.
Changes in the Board as on March 31, 2026
1. Mr. Anoop Moopen (DIN: 02301362) resigned from the position of Non-Executive
Director of the Company with effect from November 06, 2025.
2. Mr. Emmanuel David Gootam (DIN: 09771151) ceased to be an Independent Director of
the Company upon completion of his tenure. The Board expresses its gratitude for their
valuable contributions and guidance during their association with the Company.
Key Managerial Personnel
Pursuant to the provisions of Section 203 of the Act, the following are the Key
Managerial Personnel as on March 31, 2026:
S. No Name of the Key Managerial Personnel |
Designation |
| 1 Dr. Azad Moopen1&2 |
Chairman and Managing |
|
Director |
| 2 Ms. Alisha Moopen2 |
Deputy Managing Director |
| 3 Mr. Sunil Kumar M R |
Chief Financial Officer |
| 4 Mr. Hemish Purushottam |
Company Secretary and |
|
Compliance Officer |
1 Dr. Azad Moopen ceased to be the Managing Director of the Company with effect from
April 14, 2026, upon completion of his tenure. Subsequently, he was appointed as an
Executive Director of the Company with effect from April 15, 2026, pursuant to the
approval of the shareholders by way of a Special Resolution passed through postal ballot
on April 12, 2026.
2 Dr. Azad Moopen and Ms. Alisha Moopen ceased to be a Key Managerial Personnel of the
Company with effect from 1 July 2026 under Section 203 of the Act, while they continue to
be Directors of the Company.
Changes in the Directors and Key Managerial Personnel after 31 March 2026 till date of
this report
Dr. Azad Moopen's tenure as a Managing Director concluded on April 14, 2026, consequent
to which the shareholders of the Company vide a special resolution passed through postal
ballot, on April 12, 2026, approved the appointment of Dr. Azad as a
Whole-time Director designated as an Executive Chairman for a period from April 15,
2026 to May 28, 2028.
Consequent to the Scheme of Amalgamation between Quality Care India Limited
("QCIL") and the Company becoming effective on 1 July 2026, the following
changes were made to the composition of the Board:
Appointment of Directors subject to approval of shareholders through postal ballot:
1. Mr. Varun Khanna (DIN:03584124) was appointed as Managing Director & Group Chief
Executive Officer (Key Managerial Personnel) of the Company.
2. Mr. Neeraj Jain (DIN: 00348591), Mr. Kewal Handa (DIN: 00056826) and Mr. V K Mathews
(DIN: 00049414), were appointed as Independent Directors of the Company.
3. Ms. Ayshwarya Vikram (DIN: 08153649) and Mr. Ganesh Mani (DIN: 08385423) were
appointed as Non-Executive Directors of the Company.
Cessation of Directors:
1. Mr. Maniedath Madhavan Nambiar (DIN: 01122411) and Mr. C. J. George (DIN: 00003132),
resigned as Independent Directors of the Company.
2. Dr. Zeba Azad Moopen (DIN: 03604401) and Mr. Shamsudheen Bin Mohideen Mammu Haji
(DIN: 02007279) resigned as Non-Executive Directors of the Company.
The Board extended its deepest appreciation and gratitude for their exemplary guidance,
unwavering support, and valuable contributions during their respective tenures with the
Company.
13. Audit Committee
During the year under review, Mr. Emmanuel David Gootam ceased to be a Member of the
Audit Committee with effect from 9 November 2025, consequent to completion of his tenure
as an Independent Director of the Company.
As at 31 March 2026, the Audit Committee comprised of Mr. James Mathew (Chairman), Ms.
Alisha Moopen and Mr. Sunil Theckath Vasudevan (Members).
Following the effectiveness of the Scheme of Amalgamation on 1 July 2026, the Audit
Committee was reconstituted to align with the governance framework of the merged entity.
Accordingly, the Committee comprises Dr. James Mathew as Chairman and Ms. Alisha Moopen,
Mr. Sunil Theckath Vasudevan, Ms. Ayshwarya Vikram, Mr. Neeraj Jain and Mr. Kewal Handa as
Members with effect from 1 July 2026.
The powers, roles and responsibilities of the Audit Committee are set out in the
Corporate Governance Report, which forms an integral part of this Report. All
recommendations made by the Audit Committee during the year under review were duly
considered and accepted by the Board of Directors.
14. BOARD EVALUATION
Pursuant to the provisions of the Companies Act, 2013 and the SEBI Listing Regulations,
the annual performance evaluation of the Board, its Committees, Individual Directors, the
Chairman and the Management for FY 2025-26 was undertaken through an external independent
professional firm specializing in board evaluations and corporate governance assessments.
The evaluation was carried out through a structured questionnaire-based process based on
criteria approved by the Nomination and Remuneration Committee, covering, inter alia,
Board composition, governance effectiveness, strategic oversight, risk management, quality
of deliberations, leadership, participation and overall contribution.
The Independent Directors, at their separate meeting, reviewed the performance of the
Non-Independent Directors, the Chairman, the Board and its Committees in accordance with
applicable provisions of the Act and Listing Regulations. The Nomination and Remuneration
Committee reviewed the evaluation outcome and submitted its recommendations to the Board.
Based on the evaluation, the Board expressed satisfaction with the performance and
effectiveness of the Board, its Committees, Individual Directors and the Management, while
reaffirming its commitment to continuously strengthen governance standards and adopt best
practices. Further details on the performance evaluation process are provided in the
Corporate Governance Report forming part of this Annual Report.
15. BOARD POLICIES
The details of the policies approved and adopted by the Board as required under the Act
and Listing regulations are available at the website of the Company at
https://www.asterqualitycare. com/investors/corporate-governance/policies
Policy on Nomination, Remuneration and Evaluation
The Board has adopted a policy on Nomination, Remuneration and Evaluation of the Board
of Directors and Senior Management ("NRC Policy"). The NRC Policy of the Company
on directors' appointment and remuneration, including the criteria for determining
qualifications, positive attributes, independence of a director and other matters, as
required under sub-section (3) of Section 178 of the Act.
Structured Framework: Establishes clear guidelines for the appointment,
reappointment, removal, and succession planning of Directors, KMPs, and Senior Management.
Merit & Diversity Focus: Emphasizes merit-based selection with due
consideration for board diversity, including gender, skills, and experience.
Performance-Linked Remuneration: Defines a balanced remuneration structure
combining fixed pay, performance incentives, and long-term benefits aligned with industry
benchmarks.
Board Evaluation: Outlines annual performance evaluation of the Board, its
committees, and individual directors, influencing continuation and reappointment
decisions.
Independent Oversight: Ensures independent directors meet separately to review
board performance and information flow, maintaining governance standards.
Board Diversity: The Company recognises Board diversity as a key element of
effective governance and sustainable growth. The Nomination and Remuneration Committee
considers diversity, including skills, experience, gender, independence and background,
while recommending Board appointments based on merit and objective criteria. The Company
ensures compliance with applicable regulatory requirements, including the appointment of
at least one Woman Independent Director. Policy on Board diversity forms part of the NRC
Policy We affirm that the remuneration paid to the Directors is in accordance with the
terms set out in the Company's NRC Policy.
16. MEETINGS OF THE BOARD AND ITS COMMITTEES
During FY 2025-26, 9 (Nine) meetings of the Board of Directors were held, and the
details of meetings of the Board Committees held during the financial year 2025-2026 along
with information relating to attendance of each director/committee member is provided in
the Corporate Governance Report, which forms part of this Annual Report. The necessary
quorum was present for all the meetings. The maximum interval between any two Board
meetings did not exceed 120 days as prescribed under the Act.
17. SECRETARIAL STANDARDS
Your Company is in compliance with the provisions of the applicable Secretarial
Standards issued by the Institute of Company Secretaries of India ('ICSI') in terms of the
Act.
18. PARTICULARS OF EMPLOYEES
The remuneration paid to Directors, Key Managerial Personnel, and Senior Management
Personnel during FY 2025-26 was in accordance with the NRC Policy of the Company.
Disclosures pertaining to remuneration and other details as required under Section 197(12)
of the Act read with Rule 5(1) of the Companies (Appointment and Remuneration of
Managerial Personnel) Rules, 2014 are provided in the prescribed format and appended as Annexure
2 to this Report. As per the provisions of Section 197(12) of the Act read with Rule
5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel)
Rules, 2014, a statement containing names of top ten employees in terms of remuneration
drawn and the particulars of employees forms part of this report. However, in terms of the
first proviso to Section 136(1) of the Act, Annual Report excluding the aforesaid
information, is being sent to Shareholders of the Company and others entitled thereto. Any
member interested in obtaining a copy thereof, may write to the Company Secretary and
compliance officer of the Company at cs@asterqualitycare.com
19. EMPLOYEE STOCK OPTION SCHEME
The Company's has adopted and implemented Aster DM Healthcare Employee Stock Option
plan 2013 ("Scheme") and administered by the DM Healthcare Employees Welfare
Trust ('ESOP Trust') under the instructions and supervision of the Nomination and
Remuneration Committee ('NRC'). The scheme is implemented through a trust route in
accordance with the Securities and Exchange Board of India (Share Based Employee Benefits
and Sweat Equity) Regulations, 2021 ('SEBI SBEB & SE Regulations') with a view of
attracting and retaining the best talent, encouraging employees to align individual
performances with Company's objectives and promoting increased participation by them in
the growth of the Company. In accordance with the terms of ESOP Scheme, options may be
granted to employees of the Company which gives them rights to receive equity shares of
the Company having face value of INR 10/- (Indian Rupee Ten) each upon exercise.
The disclosures as required under Rule 12 of the Companies (Share Capital and
Debentures) Rules, 2014 and the applicable provisions of the SEBI SBEB & SE
Regulations have been provided separately in Annexure 3 to this Report. The said
disclosures are also available on the Company's website at https://www.
asterqualitycare.com/investors/stock-exchange-disclosures/
regulation-30-disclosures/announcements-disclosures-esop-disclosure-disclosure-of-fines-and-penalties.
There were no material changes in the Employee Stock Option Scheme during the year under
review. The Secretarial Auditor of the Company has provided a certificate stating that the
Aster DM Healthcare ESOP Plan 2013 has been implemented in accordance with the SEBI SBEB
& SE Regulations. The said certificate will be placed before the members at the
ensuing Annual General Meeting and will also be made available on the website of your
Company.
20. INTERNAL FINANCIAL CONTROL AND ITS ADEQUACY
The Company is committed to maintain a high standard of internal controls throughout
its operations. The Company has adopted policies, processes, and procedures for ensuring
orderly and efficient conduct of the business, including adherence to the Company's
policies, the safeguarding of its assets, the prevention and detection of frauds and
errors, the reasonableness and completeness of the accounting records, and the timely
preparation of reliable financial disclosures. The internal financial control system is
commensurate with the nature of business, size and complexity of operations and has been
designed to provide reasonable assurance on the achievement of objectives, effectiveness
and efficiency of operations, reliability of financial reporting and compliance with
applicable statutory laws and regulations. The Internal Financial Control system is
designed to manage rather than to eliminate the risk of failure to achieve business
objectives. The same is designed to ensure that all transactions are evaluated,
authorized, recorded and reported accurately. As part of the Corporate Governance Report,
Chief Financial Officer (CFO) certification is provided, for assurance on the existence of
effective internal financial control systems and procedures in the Company. The internal
control framework is supplemented with an internal audit program that provides an
independent view of the efficacy and effectiveness of the process and control environment
and supports a continuous improvement program. The internal audit program is managed by an
in-house internal audit function and supported by the co-sourced internal audit team, KPMG
Assurance and Consulting Services LLP, which is an external firm. The Audit Committee of
the Board oversees the internal audit function, including review of the internal audit
plan, which is prepared based on adequate risk assessment of the company's operations.
The Audit Committee is regularly apprised by the internal auditors and co-sourced
internal auditors through various reports and presentations. The scope and authority of
the internal audit function is derived from the audit charter approved by the Audit
Committee. The internal audit function develops an internal audit plan to assess process,
controls' design and operating effectiveness, as per the risk assessment methodology. The
internal audit function provides assurance to the Board that a system of internal control
is designed and deployed to manage key business risks and is operating effectively. The
Audit Committee also reviews the effectiveness of the implementation of the mitigation
actions designed and implemented by management to remediate any gaps.
21. VIGIL MECHANISM
The Company believes in conducting its affairs in a transparent manner, in compliance
with statutory requirements and adopts the highest standards of professionalism and
ethical behaviour. Integrity is one of the Company's key values, which it strictly abides
by. Keeping that in view the Company has established a vigil mechanism for Directors,
employees and other personnel to report concerns about unethical behaviour, actual or
suspected fraud or violation of the Company's code of conduct or ethics. The Whistle
Blower Policy is available on the website of the Company at
https://www.asterqualitycare.com/storage/
fileadmin/user_upload/Whistle_Blower_policy_1.pdf The Company, as a policy, condemns any
kind of discrimination, harassment, victimization, or any other unfair employment practice
being adopted against whistle blowers and provides adequate safeguard measures. It also
provides to the complainant, direct access to the Chairman of the Audit Committee to raise
concerns, in exceptional cases. It is affirmed that no person has been denied access to
the Audit Committee. In addition to this, the Company has also engaged an independent
agency called 'Integrity Matters' that provides an electronic and digital platform to
report any unethical practices or harassment/injustice at the workplace confidentially
and, if desired, anonymously by the complainant anywhere in the world to ensure fairness
and transparency in the process. The Audit Committee reviews the status of whistleblowers
complaints, including actions taken, remedial measures, etc., every quarter.
22. RISK MANAGEMENT POLICY & RESILIENCE
During the period under review, the Company has strategized to handle the risks by:
carrying out risk identification sessions for the Board, Senior Management, and other
staff members. defining, analysing and prioritizing various kinds of risks. defining the
key mitigation strategies to reduce the impact / probability of occurrence of the risks.
defining the key risk indicators, to measure the exposure of the risks.
giving frequent training and support to the risk owners, employees, and others as
appropriate; and regular review of the risk portfolio and presentation to the Risk
Management Committee. The development and implementation of risk management policy has
been covered in the Management Discussion and Analysis, which forms part of this report.
The Risk Management Policy is available on the website of the Company at
https://www.asterqualitycare.com/storage/
fileadmin/user_upload/Risk_Management_Policy__Final.pdf.
23. CORPORATE SOCIAL RESPONSIBILITY ("CSR")
The Company's CSR Policy reflects its commitment to sustainable and inclusive growth
and provides the framework for undertaking CSR initiatives aimed at creating long-term
social value and contributing to the well-being and development of communities in areas
where the Company operates.
In accordance with Section 135 of the Companies Act, 2013 read with Rule 8(1) of the
Companies (Corporate Social Responsibility Policy) Rules, 2014, the Annual Report on CSR
activities, together with the details of the composition of the CSR Committee, is annexed
to this Board's Report as Annexure 4.
24. AUDITORS
Statutory Auditors
In terms of Section 139 of the Act read with the Companies (Audit and Auditors) Rules,
2014, M/s. Deloitte Haskins & Sells LLP, Chartered Accountants (ICAI Firm Registration
No. 008072S) were appointed as the statutory auditors of the Company, to hold office for
the second term of five consecutive years from the conclusion of the 17th AGM
of the Company till the conclusion of the 22nd AGM.
Secretarial Auditors
Pursuant to the provisions of Section 204 of the Act read with the Companies
(Appointment and Remuneration of Managerial Personnel) Rules, 2014, M/s. S Sandeep &
Associates, Company Secretaries (ICSI Firm registration no: S2010TN133300), were appointed
as secretarial auditors of the Company to hold office for a term of five consecutive
financial years commencing from April 1, 2025 till March 31, 2030.
Cost Auditor
The Company has maintained cost records and accounts as specified by the Central
Government under Section 148(1) of the Act, and rules made thereunder and M/s. Jitender,
Navneet & Co, Cost Accountants [Firm Registration No: 000119] were appointed as the
Cost Auditor of the Company to conduct the audit of cost records for the financial year
2025-26. The Board of Directors, on the recommendation of the Audit Committee, have
reappointed M/s. Jitender, Navneet & Co, Cost Accountants as the Cost Auditor of the
Company to conduct the audit of cost records for the financial year 2026-27 at a
remuneration of INR 2,75,000/- (Rupees Two Lakhs and Seventy Five Thousand only) plus out
of pocket expenses & taxes as applicable, if any, in connection with the cost audit.
The Board of Directors of your Company has recommended the ratification of remuneration of
M/s. Jitender, Navneet & Co, Cost Accountants for financial year 2026-27 at the
ensuing Annual General Meeting. The Notice of 18th Annual General Meeting of
the Company contains the above proposal for the approval of the Members.
25. AUDIT REPORTS
Statutory Audit Report
The Auditors' Report provided by M/s. Deloitte Haskins & Sells LLP for the
financial year ended March 31, 2026, is enclosed along with the financial statements in
the Annual Report. The Auditors' Report does not contain any qualifications, observations
or adverse remarks.
During the year under review, the Statutory Auditors have not reported to the Audit
Committee any incident of material fraud committed against the Company by its officers or
employees under Section 143 (12) of the Act.
Secretarial Audit Report
The Secretarial Audit report issued by M/s. S Sandeep
& Associates, Secretarial Auditors for the financial year 2025-26 is annexed
as Annexure 5 to this report. The report does not contain qualification,
reservation or adverse remark.
Pursuant to Regulation 24A of the Listing Regulations, the Secretarial Audit report of
Malabar Institute of Medical Sciences Ltd, a material unlisted subsidiary of the Company
issued by M/s. Ashique Sameer Associates, Practising Company Secretaries for the financial
year 2025-26 is annexed as Annexure 5A to this report.
During the year under review, the Secretarial Auditors have not reported to the Audit
Committee any incident of fraud committed against the Company by its officers or employees
under Section 143 (12) of the Act.
26. MATERIAL CHANGES AND COMMITMENTS, IF ANY
Your Board is pleased to report the successful completion of the amalgamation of
Quality Care India Limited ("QCIL") with the Company, pursuant to the Scheme of
Amalgamation sanctioned by the Hon'ble National Company Law Tribunal, Hyderabad Bench, on
19 June 2026. The Scheme became effective on 1 July 2026 and marks a defining milestone in
the Company's evolution.
The combination brings together two leading healthcare platforms with strong clinical
excellence, complementary regional presence and a shared commitment to patient-centric
care. The merged entity has emerged as one of India's largest integrated healthcare
providers, with an expanded network of hospitals and healthcare facilities, enhanced
scale, and strengthened capabilities to pursue sustainable long-term growth.
The amalgamation has materially enhanced the Company's financial and operational
profile and is expected to unlock significant synergies, strengthen competitive
positioning and create enduring value for shareholders, patients, employees and other
stakeholders.
27. ANNUAL RETURN
Pursuant to Section 92(3) of the Act and Rule 12 of the Companies (Management and
Administration) Rules, 2014, the Annual Return for FY 2025-26 is available on the Company's
website at https://www.asterqualitycare.com/ investors/corporate-governance/annual-return
28. SIGNIFICANT AND MATERIAL ORDERS
There are no significant or material orders passed by any regulators, courts, or
tribunals impacting the going concern status and the Company's operations in future.
29. CHANGES IN NATURE OF BUSINESS
The Company did not undergo any change in the nature of its business during the year
under review.
30. DISCLOSURE OF CERTAIN TYPES OF AGREEMENTS BINDING THE COMPANY
There are no agreements impacting management or control of the Company or imposing any
restriction or creating any liability upon the Company in the financial year 2025-26.
31. DISCLOSURE UNDER SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION
& REDRESSAL) ACT, 2013
The Company is committed to maintaining a safe, respectful, and inclusive workplace and
has zero tolerance for any form of sexual harassment. In line with the provisions of the
Sexual Harassment of Women at Workplace (Prevention, Prohibition &
Redressal) Act, 2013, as amended, the Company has in place a comprehensive Prevention
of Sexual Harassment ("POSH") Policy, applicable to all employees, including
permanent, contractual, temporary employees and trainees.
To ensure effective redressal of grievances, Internal Committees ("IC") under
POSH have been duly constituted across locations in accordance with statutory
requirements. Each IC comprises internal members and an external member who has expertise
and experience in this field. The ICs are responsible for receiving, investigating, and
resolving complaints in a timely and confidential manner while ensuring principles of
natural justice. The Company also undertakes ongoing awareness and sensitization
initiatives to promote a respectful workplace culture and to enable employees to
understand their rights and responsibilities under the POSH framework. Adequate safeguards
are in place to protect complainants and witnesses against any form of retaliation.
Details of complaints received and disposed of during the year under review are as
under:
Particulars |
No. of complaints* |
| Number of complaints of sexual |
23 |
| harassment received |
|
| Number of complaints disposed |
23 |
| Number of cases pending for more |
0 |
| than 90 days |
|
* The above information is provided on a consolidated basis.
32. COMPLIANCE WITH MATERNITY BENEFIT ACT, 1961
The Company remains committed to fostering an inclusive, equitable, and
employee-centric workplace by ensuring full compliance with the provisions of the
Maternity Benefit Act, 1961.
Maternity benefits provided by the Company are designed to support female employees
through all stages of motherhood, including childbirth and adoption. The Company currently
administers these benefits in accordance with the statutory framework. While no standalone
internal policy has been formalised, the applicable provisions are embedded within HR
practices and employment terms to ensure consistent implementation across the
organisation. Through these measures, the Company reinforces its commitment to employee
well-being and gender-inclusive workplace practices, contributing to the overall health
and welfare of both the employee and her child.
33. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREX EARNINGS AND OUTGO
Details of the energy conservation, technology absorption and foreign exchange earnings
and outgo as stipulated under Section 134(3)(m) of the Act read with Rule 8 of the
Companies (Account) Rules, 2014 are annexed to this Report as Annexure 6.
34. MANAGEMENT DISCUSSION AND ANALYSIS
In terms of the provisions of Regulation 34 (3) of the Listing Regulations, the
Management Discussion and Analysis forms part of this Integrated Annual report.
35. CORPORATE GOVERNANCE
As per Regulation 34 and Schedule V (C) to the Listing Regulations, the Corporate
Governance Report along with the Compliance Certificate for the year under review, as
stipulated under SEBI Listing Regulations forms part of the Annual Report and the same is
annexed as Annexure 7.
36. PROCEEDINGS UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016
No proceedings are initiated/pending against the Company under the Insolvency and
Bankruptcy Code, 2016.
37. BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORT
Pursuant to Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 and the applicable SEBI circulars issued thereunder, the
Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26
forms an integral part of this Annual Report. In accordance with the requirements
stipulated by Circular No.: SEBI/HO/CFD/CFD-PoD-1/P/CIR/2025/42 dated 28 March 2025, the
Company has obtained independent assurance on the applicable BRSR Core disclosures. The
assurance report is included as part of the BRSR and reinforces the reliability,
transparency and robustness of the Company's sustainability reporting framework.
38. DIRECTORS' RESPONSIBILITY STATEMENT
Pursuant to Section 134(5) of the Act, the Board of Directors, to the best of its
knowledge and ability, confirm that: a) In the preparation of the annual accounts, the
applicable accounting standards have been followed and there has been no material
departures; b) the Directors have selected such accounting policies and applied them
consistently and made judgments and estimates that are reasonable and prudent so as to
give a true and fair view of the state of affairs of the Company at the end of the
financial year and of the profit and loss of the Company for that period; c) the Directors
have taken proper and sufficient care for the maintenance of adequate accounting records
in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets
of the Company and for preventing and detecting fraud and other irregularities; d) the
Directors have prepared the annual accounts on a going concern basis; e) they have laid
down internal financial controls to be followed by the Company, which are adequate and are
operating effectively; f) they have devised proper systems to ensure compliance with the
provisions of all applicable laws and such systems are adequate and operating effectively.
39. ACKNOWLEDGEMENT
We thank our Shareholders, Customers, Banks, Financial Institutions, and well-wishers
for their continued support during the year. We place on record their appreciation for the
contribution made by the employees at all levels. The Company's consistent growth was made
possible by their hard work, solidarity, co-operation, and support. The Board sincerely
expresses its gratitude to Government of India, Ministry of Corporate Affairs, Reserve
Bank of India, Foreign Investment Promotion Board, Securities and Exchange Board of India,
BSE Limited, National Stock Exchange of India Limited and Governments of Kerala,
Karnataka, Andhra Pradesh, Telangana, Tamil Nadu and Maharashtra for the guidance and
support received from them including officials thereat from time to time.
|